Volume 12 Supplement 1

Abstracts from the First International Science Symposium on HIV and Infectious Diseases (HIV SCIENCE 2012)

Open Access

Transcriptional modulation of HIV-1C LTR promoter

  • Anand Singh1Email author,
  • Pradeep Ramalingam1,
  • Jayanth Kumar Palanichamy1,
  • Mohita Bhagat1,
  • Muzaffer Ahmad Kassab1,
  • Subrata Sinha1 and
  • Parthaprasad Chattopadhyay1
BMC Infectious Diseases201212(Suppl 1):O6

DOI: 10.1186/1471-2334-12-S1-O6

Published: 4 May 2012

Background

All current anti-HIV1 therapies target the viral proteins or RNA; however targeting HIV1 at the transcriptional level of the integrated provirus has been less explored. In India, AIDS is commonly caused by HIV-1C compared to HIV-1B in developed countries. HIV1-5’LTR acts as a promoter and shows sequence variation among different clades. Transcriptional gene silencing (TGS) is a method wherein dsRNA targeting the promoter/enhancer of a gene are used to down regulate its expression.

Methods

We used SiHa cell line stably expressing a bi-cistronic reporter system (5’LTR-SEAP-IRES-EGFP), in which secreted alkaline phosphatase (SEAP) and enhanced green fluorescent protein (EGFP) are expressed under 5’LTR of HIV-1B/C. The cell line was transfected with different dsRNAs (S1-S6) targeting the core promoter/enhancer of HIV-1C LTR to induce TGS. Screening for decreased transcription was done using real-time PCR (mRNA expression of SEAP and EGFP), fluorescence microscopy (EGFP) and flow cytometry (EGFP).

Results

After single or multiple (thrice) transfection of dsRNAs, we identified one dsRNA (S4) which showed consistent and significant down regulation of both SEAP (44% & 68% respectively) and EGFP (40% & 65%) (p<0.001 in both cases) mRNA levels. This reporter down regulation was also confirmed by studying EGFP expression using fluorescence microscopy and flowcytometry which also showed a significant fall after S4 transfection.

Conclusion

TGS usually involves epigenetic modifications like DNA methylation/histone methylation at the targeted region and induces long term suppression of gene expression. So targeting of the HIV-1C LTR by dsRNA can be used as a therapeutic modality in the future.

Authors’ Affiliations

(1)
All India Institute of Medical Sciences (AIIMS)

Copyright

© Singh et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement